Geron [GERN] vs Zymeworks [ZYME] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Geron Corporation wins in 9 metrics, Zymeworks Inc. wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Geron Corporation | Zymeworks Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -11.54 | 3.79 | Zymeworks Inc. |
| Price-to-Book Ratio | 4.31 | 7.32 | Geron Corporation |
| Debt-to-Equity Ratio | 54.01 | 6.80 | Zymeworks Inc. |
| PEG Ratio | -0.46 | 0.05 | Zymeworks Inc. |
| EV/EBITDA | -14.19 | -20.40 | Geron Corporation |
| Profit Margin (TTM) | -45.41% | -76.56% | Geron Corporation |
| Operating Margin (TTM) | -17.72% | -1,755.55% | Geron Corporation |
| Return on Equity | -32.99% | -26.72% | Zymeworks Inc. |
| Return on Assets (TTM) | -5.54% | -14.29% | Geron Corporation |
| Free Cash Flow (TTM) | $-111.09M | $-35.36M | Zymeworks Inc. |
| 1-Year Return | -17.76% | 119.86% | Zymeworks Inc. |
| Price-to-Sales Ratio (TTM) | 5.30 | 18.46 | Geron Corporation |
| Enterprise Value | $724.89M | $1.73B | Zymeworks Inc. |
| EV/Revenue Ratio | 3.94 | 16.33 | Geron Corporation |
| Gross Profit Margin (TTM) | 97.28% | N/A | N/A |
| Revenue per Share (TTM) | $0 | $1 | Zymeworks Inc. |
| Earnings per Share (Diluted) | $-0.13 | $-1.08 | Geron Corporation |
| Beta (Stock Volatility) | 0.67 | 1.20 | Geron Corporation |
| Short % of Float | 11.97% | 8.16% | Zymeworks Inc. |
Geron Corporation vs Zymeworks Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Geron Corporation | -0.85% | -8.59% | -25.48% | -24.52% | -4.88% | -11.36% |
| Zymeworks Inc. | 1.00% | -5.08% | -9.97% | 3.43% | -3.94% | -9.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Geron Corporation | -17.76% | -65.28% | -10.07% | -57.77% | -69.06% | -80.95% |
| Zymeworks Inc. | 119.86% | 189.85% | -20.78% | 93.31% | 93.31% | 93.31% |
Performance & Financial Health Analysis: Geron Corporation vs Zymeworks Inc.
| Metric | GERN | ZYME |
|---|---|---|
| Market Information | ||
| Market Cap | $961.35M | $1.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 16,575,461 | 626,460 |
| 90 Day Avg. Volume | 19,481,744 | 729,503 |
| Last Close | $1.16 | $24.35 |
| 52 Week Range | $1.04 - $2.01 | $11.51 - $29.75 |
| % from 52W High | -42.29% | -18.15% |
| All-Time High | $71.72 (Feb 28, 2000) | $59.03 (Jan 11, 2021) |
| % from All-Time High | -98.38% | -58.75% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | -0.92% |
| Quarterly Earnings Growth | 0.01% | -0.92% |
| Financial Health | ||
| Profit Margin (TTM) | -0.45% | -0.77% |
| Operating Margin (TTM) | -0.18% | -17.56% |
| Return on Equity (TTM) | -0.33% | -0.27% |
| Debt to Equity (MRQ) | 54.01 | 6.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.35 | $3.60 |
| Cash per Share (MRQ) | $0.56 | $3.10 |
| Operating Cash Flow (TTM) | $-111,037,000 | $-33,005,000 |
| Levered Free Cash Flow (TTM) | $-78,356,248 | $-12,959,125 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Geron Corporation vs Zymeworks Inc.
| Metric | GERN (Apr 24, 2026) | ZYME (Apr 13, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -11.54 | 3.79 |
| Forward P/E | 25.33 | 33.43 |
| PEG Ratio | -0.46 | 0.05 |
| Price to Sales (TTM) | 5.30 | 18.46 |
| Price to Book (MRQ) | 4.31 | 7.32 |
| Market Capitalization | ||
| Market Capitalization | $961.35M | $1.96B |
| Enterprise Value | $724.89M | $1.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.94 | 16.33 |
| Enterprise to EBITDA | -14.19 | -20.40 |
| Risk & Other Metrics | ||
| Beta | 0.67 | 1.20 |
| Book Value per Share (MRQ) | $0.35 | $3.60 |
Financial Statements Comparison: Geron Corporation vs Zymeworks Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | GERN (2025) | ZYME (2025) |
|---|---|---|
| Revenue/Sales | 183.88M | 105.97M |
| Cost of Goods Sold | 4.75M | N/A |
| COGS % of Revenue | 2.6% | 0.0% |
| Gross Profit | 179.14M | N/A |
| Gross Margin | 97.4% | 0.0% |
| Research & Development | 71.43M | 137.00M |
| Operating Income (EBIT) | -51.55M | -92.54M |
| Operating Margin | -28.0% | -87.3% |
| EBITDA | -32.61M | -80.82M |
| EBITDA Margin | -17.7% | -76.3% |
| Pre-Tax Income | -83.50M | -79.75M |
| Pre-Tax Income % of Revenue | -45.4% | -75.3% |
| Income Tax | N/A | 1.38M |
| Income Tax % of Revenue | 0.0% | 1.3% |
| Net Income (Profit) | -83.50M | -81.13M |
| Profit Margin | -45.4% | -76.6% |
Balance Sheet & Liquidity Metrics
| Metric | GERN (2025) | ZYME (2025) |
|---|---|---|
| Cash & Equivalents | 77.56M | 41.16M |
| Total Current Assets | 520.27M | 248.77M |
| Total Current Assets % of Revenue | 282.9% | 234.8% |
| Total Current Liabilities | 111.54M | 42.32M |
| Total Current Liabilities % of Revenue | 60.7% | 39.9% |
| Long-Term Debt | 120.99M | 14.80M |
| Long-Term Debt % of Revenue | 65.8% | 14.0% |
| Total Shareholders Equity | 225.87M | 268.50M |
| Retained Earnings | -1.86B | -953.16M |
| Retained Earnings % of Revenue | -1,009.3% | -899.5% |
| Property, Plant & Equipment | 0 | 29.56M |
Cash Flow Statement Comparison
| Metric | GERN (2025) | ZYME (2025) |
|---|---|---|
| Operating Cash Flow | -118.43M | -40.00M |
| Operating Cash Flow % of Revenue | -64.4% | -37.7% |
| Capital Expenditures | -49,000 | -1.52M |
| Free Cash Flow | -111.09M | -35.36M |
| FCF Margin | -60.4% | -33.4% |
| Debt Repayment | 0 | N/A |
| Common Stock Repurchase | N/A | -41.70M |
Short Interest & Institutional Ownership Analysis
| Metric | GERN | ZYME |
|---|---|---|
| Shares Short | 76.67M | 4.08M |
| Short Ratio | 4.30 | 5.42 |
| Short % of Float | 11.97% | 8.16% |
| Shares Outstanding | 639.86M | 75.19M |
| Float Shares | 510.78M | 72.80M |
| % Held by Insiders | 0.08% | 1.26% |
| % Held by Institutions | 77.92% | 98.45% |
| % Held by Public | 22.00% | 0.29% |
Dividend Analysis & Yield Comparison: Geron Corporation vs Zymeworks Inc.
| Metric | GERN | ZYME |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |